Signal detection to identify serious adverse events (neuropsychiatric events) in travelers taking mefloquine for chemoprophylaxis of malaria
Cho Naing,1,3 Kyan Aung,1 Syed Imran Ahmed,2 Joon Wah Mak3
1School of Medical Sciences, 2School of Pharmacy and Health Sciences, 3School of Postgraduate Studies and Research, International Medical University, Kuala Lumpur, Malaysia
Background: For all medications, there is a trade-off between benefits and potential for harm. It is important for patient safety to detect drug-event combinations and analyze by appropriate statistical methods. Mefloquine is used as chemoprophylaxis for travelers going to regions with known chloroquine-resistant Plasmodium falciparum malaria. As such, there is a concern about serious adverse events associated with mefloquine chemoprophylaxis. The objective of the present study was to assess whether any signal would be detected for the serious adverse events of mefloquine, based on data in clinicoepidemiological studies.
Materials and methods: We extracted data on adverse events related to mefloquine chemoprophylaxis from the two published datasets. Disproportionality reporting of adverse events such as neuropsychiatric events and other adverse events was presented in the 2 × 2 contingency table. Reporting odds ratio and corresponding 95% confidence interval [CI] data-mining algorithm was applied for the signal detection. The safety signals are considered significant when the ROR estimates and the lower limits of the corresponding 95% CI are ≥2.
Results: Two datasets addressing adverse events of mefloquine chemoprophylaxis (one from a published article and one from a Cochrane systematic review) were included for analyses. Reporting odds ratio 1.58, 95% CI: 1.49–1.68 based on published data in the selected article, and 1.195, 95% CI: 0.94–1.44 based on data in the selected Cochrane review. Overall, in both datasets, the reporting odds ratio values of lower 95% CI were less than 2.
Conclusion: Based on available data, findings suggested that signals for serious adverse events pertinent to neuropsychiatric event were not detected for mefloquine. Further studies are needed to substantiate this.
Keywords: mefloquine, signal detection, reporting odds ratio, neuropsychiatric events
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]
Readers of this article also read:
Powell DR, Doree D, Jeter-Jones S, Ding ZM, Zambrowicz B, Sands A
Published Date: 26 February 2015
de Araújo AN, de Sena EP, de Oliveira IR, Juruena MF
Published Date: 29 November 2012
Self-initiation of antiretroviral therapy in the developing world: the involvement of private pharmacies in an HIV program
Minzi OM, Buma D, Kagashe GA
Published Date: 29 March 2012
Published Date: 26 March 2012
Nabeta K, Kimura M, Ohkura M, Tsuchiya F
Published Date: 24 February 2012
Kheir N, El Hajj MS, Wilbur K, Kaissi RML, Yousif A
Published Date: 20 December 2011
Safety aspects and rational use of a naproxen + esomeprazole combination in the treatment of rheumatoid disease
David N Roberts, Philip B Miner
Published Date: 3 March 2011
Luca Dalle Carbonare, Mirko Zanatta, Adriano Gasparetto, et al
Published Date: 19 August 2010
Development of indicators for identifying adverse drug events in an Indian tertiary care teaching hospital
Rajakannan Thiyagu, Surulivel R Mallayasamy, Valakkathala Rajesh, et al
Published Date: 30 June 2010
C-J Törnhage, G Brunlöf, S M Wallerstedt
Published Date: 31 March 2009